<DOC>
	<DOCNO>NCT01483924</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics efficacy 12 week treatment Apo805K1 subject moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Study Evaluate Apo805K1 Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>A ) To evaluate safety tolerability 12 week treatment Apo805K1 B ) To evaluate pharmacokinetics Apo805K1 follow daily administration 14 day C ) To evaluate efficacy pharmacodynamics Apo805K1</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Main A clinical diagnosis moderate severe chronic plaque psoriasis least 6 month ( Baseline assessment ) current body surface area ( BSA ) involvement ≥10 % Psoriasis Area Severity Index ( PASI ) ≥10 . Male female subject 18 65 year age , inclusive . At least one psoriatic plaque ≥6 mm diameter ( location suitable biopsy ) . Signed witness write informed consent form obtain prior first study intervention , well ability adhere study restriction , appointment evaluation schedule . Main Treatment psoriasis biologic agent within 90 day prior Baseline assessment study . Treatment methotrexate , cyclosporine , retinoids , hydroxyurea systemic agent within 30 day prior Baseline assessment study . Phototherapy within 30 day prior Baseline assessment study . Psoriasis topical therapy within 14 day prior Baseline assessment study ( exception : nonmedicated emollient tar shampoo allow ) . History liver disease abnormal liver enzyme Serum creatinine ≥1.5 time upper limit normal age sexmatched control . Previous treatment Apo805K1or Thymodepressin immunosuppressant drug . Evidence skin condition psoriasis ( e.g. , eczema ) could interfere psoriasis assessment . History chronic infection malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Mild Moderate Chronic Plaque Psoriasis</keyword>
</DOC>